Novartis Snaps Up KRAS Inhibitor R&D
Difficult-To-Target Oncogenic Proteins Yield To Drug Discovery
Novartis has taken an option on novel inhibitors of the KRAS cell signaling pathway while it funds the drug discovery research at the Cancer Research UK’s Beatson Institute.
